Viswanathan Swaminathan
Psychiatry · Plymouthy, NCNPI 1376568550
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,400 of the $19,621 with a category attached, or 68.3%. AbbVie accounts for 74.9% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $13,917 and has fallen 94.6% since, to $745 in 2025. Among psychiatry clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 297 payments — averaging $66.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$15K
- Alkermes, Inc.$952
- Otsuka America Pharmaceutical, Inc.$709
- Johnson & Johnson$622
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$453
- Neurocrine Biosciences, Inc.$385
- plus $2K from 14 others
What the payments were for
- Speaking & faculty fees$13,40068%
- Travel & lodging$5023%
- Food & beverage$5,67129%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 65 | $14,702 |
| Alkermes, Inc. | 42 | $952 |
| Otsuka America Pharmaceutical, Inc. | 32 | $709 |
| Johnson & Johnson | 25 | $622 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $453 |
| Neurocrine Biosciences, Inc. | 16 | $385 |
| Sunovion Pharmaceuticals Inc. | 30 | $323 |
| Teva Pharmaceuticals USA, Inc. | 14 | $245 |
| Vanda Pharmaceuticals Inc. | 11 | $223 |
| Lundbeck LLC | 10 | $219 |
| Avanir Pharmaceuticals, Inc. | 6 | $211 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $171 |
| Eisai Inc. | 6 | $99 |
| E.r. Squibb & Sons, L.L.C. | 3 | $69 |
| Corium, LLC | 3 | $61 |
| Acadia Pharmaceuticals Inc | 1 | $44 |
| Indivior Inc. | 3 | $42 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,621 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 154 | $502,528 |
| VraylarCariprazine Hcl | 181 | $267,533 |
| IngrezzaValbenazine Tosylate | 15 | $123,414 |
| Risperidone ErRisperidone Microspheres | 12 | $25,265 |
| ZyprexaOlanzapine | 17 | $16,630 |
| Clozapine | 101 | $12,288 |
| TrintellixVortioxetine Hydrobromide | 26 | $12,106 |
| BelsomraSuvorexant | 21 | $9,247 |
| ProzacFluoxetine Hcl | 12 | $9,177 |
| Risperidone | 508 | $7,742 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $7,414 |
| Benztropine Mesylate | 425 | $7,038 |
| Lurasidone Hcl | 82 | $6,808 |
| Quetiapine Fumarate | 327 | $6,582 |
| Fluphenazine Decanoate | 72 | $6,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $622 | $502,528154 claims |
| AbbVieVraylar | $14,702 | $267,533181 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $385 | $123,41415 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $171 | $19,52038 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Plymouthy
- Craig ChepkeHuntersville$4.1M
- Mark ReynoldsDurham$3.2M
- James BarkerHickory$2.1M
- Brian FarahWinston Salem$605K
- Krishna TalluriMorrisville$591K
- Ramesh GihwalaGastonia$545K
- Keshavpal ReddyGreensboro$480K
- Robert MilletRaleigh$476K
- Steven SzaboDurham$360K
- David JoyeAlbemarle$280K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.